[Skip to Content]
[Skip to Content Landing]
Negative Results
October 19, 1964

Norethynodrel With Mestranol in Treatment of Rheumatoid Arthritis

Author Affiliations

New York; Shrewsbury, Mass

From the Rheumatic Disease Unit, Division of Medicine, and the Department of Gynecology, Division of Surgery, Montefiore Hospital; the Study Group on Rheumatic Disease, New York University School of Medicine; and the Worcester Institute for Experimental Research.

JAMA. 1964;190(3):235. doi:10.1001/jama.1964.03070160059013

THE AVAILABILITY of a 19-nor progestational compound mixed with a small amount of estrogenic substance provided the opportunity to study the effect of the pseudopregnant state of the course of rheumatoid arthritis in a selected group of patients.

Seventeen patients, 13 females and four males, participated in the blindfold study. All had active rheumatoid arthritis not controlled by their current therapeutic regimens, which included corticoid analogues in five cases. The study was conducted over a period of 12 months. Each patient received medication for six months and placebo for six months, both in tablet form. Medication consisted of norethynodrel with mestranol (Enovid), a mixture of the progestogen and approximately 1.5% of the estrogen. Placebo tablets were sugar, identical in appearance with the medication.

Patients were divided into two groups, selected on an alternate basis: (1) those who received medication for the first six months and placebo thereafter, and (2) those

First Page Preview View Large
First page PDF preview
First page PDF preview